EGFR and non-small cell lung carcinoma: The study “A Landscape of Pharmacogenomic Interactions in Cancer” and the study “EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: A retrospective analysis” came in second (TC = 1043) and third place (TC = 884), respectively.